This article is more than 5 years old. Information may no longer be current.

Top 10 stories from ASCO Annual Meeting

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

This year’s ASCO Annual Meeting featured potentially practice-changing studies, including many that evaluated investigational immunotherapy agents and assessed new methods for cancer detection and prevention.

HemOnc Today presents 10 updates from the meeting that highlight key oncology research advances.

• Adjuvant FOLFIRINOX chemotherapy improved OS and PFS compared with gemcitabine among patients with surgically removed nonmetastatic pancreatic ductal adenocarcinoma. Read more.
• Chimeric antigen receptor T-cell therapy bb2121 (Bluebird Bio) demonstrated continued efficacy and safety among patients with relapsed or refractory multiple myeloma. Read more.
• Aromatase inhibitor-associated arthralgia symptoms improved among women with breast cancer and a high BMI after treatment with omega-3 fatty acids. Read more.
• High-dose proton pump inhibitors in combination with low-dose aspirin may prevent the development of esophageal cancer among patients with Barrett’s esophagus. Read more.
• The addition of adjuvant chemotherapy to endocrine therapy did not appear to benefit women with hormone receptor-positive, HER-2-negative, axillary node-negative breast cancer with a midrange recurrence score on a 21-tumor gene expression assay (Oncotype DX Breast Recurrence Score, Genomic Health). These findings suggested this patient population — which represented two-thirds of the trial cohort — can safely be spared chemotherapy after surgery. Read more.
• JTX-2011 (Jounce Therapeutics) monotherapy or in combination with nivolumab (Opdivo, Bristol-Myers Squibb) appeared well tolerated and induced antitumor responses among patients previously treated for gastric cancer and triple-negative breast cancer. Read more.
• Three prototype sequencing assays effectively detected early-stage lung cancer in blood samples. Read more.
• The combination of the CD122-based agonist NKTR-214 (Nektar) with nivolumab appeared well tolerated with promising efficacy among patients with a variety of advanced tumor types. Read more.
• Microsatellite instability-high tumors predicted occurrence of Lynch syndrome across various cancer types, not just cancers commonly known to be associated with the disease. Read more.
• Intralesional agent SD-101 (Dynavax) plus pembrolizumab (Keytruda, Merck) induced a high response rate with a tolerable safety profile among a small cohort of patients with metastatic melanoma. Read more.